Xiidra. Zaltrap. Gilotrif. Taltz.

What those words have in common, other than sounding like minor “Star Wars” characters, is that each is the name of a marketed drug. And, as such, each has been through the fantastic voyage by which humble molecules get white-boarded, focus-grouped, and lawyered-up on the way to having their names (and bountiful side effects) read aloud on the TV commercials that dot your nightly news.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy